Joseph I. Clark

26.1k total citations · 5 hit papers
122 papers, 7.4k citations indexed

About

Joseph I. Clark is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Joseph I. Clark has authored 122 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 42 papers in Molecular Biology. Recurrent topics in Joseph I. Clark's work include Cancer Immunotherapy and Biomarkers (42 papers), Renal cell carcinoma treatment (36 papers) and CAR-T cell therapy research (22 papers). Joseph I. Clark is often cited by papers focused on Cancer Immunotherapy and Biomarkers (42 papers), Renal cell carcinoma treatment (36 papers) and CAR-T cell therapy research (22 papers). Joseph I. Clark collaborates with scholars based in United States, Israel and United Kingdom. Joseph I. Clark's co-authors include Dmitry I. Gabrilovich, David P. Carbone, Bond Almand, Kim Margolin, Michael B. Atkins, Nicholas R. English, Stella C. Knight, Ekaterina Nikitina, Theodore F. Logan and Robert C. Flanigan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Joseph I. Clark

115 papers receiving 7.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer

2001 1.1k citations Bond Almand, Joseph I. Clark et al. The Journal of Immunology profile →
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

2012 826 citations Kim Margolin, Marc S. Ernstoff et al. profile →
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

2004 598 citations Joseph I. Clark, Lawrence E. Flaherty et al. profile →
Clinical significance of defective dendritic cell differentiation in cancer.

2000 569 citations Bond Almand, Joseph I. Clark et al. PubMed profile →
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

2013 486 citations Joseph I. Clark et al. profile →

Peers

Countries citing papers authored by Joseph I. Clark

Since Specialization

Citations

This map shows the geographic impact of Joseph I. Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph I. Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph I. Clark more than expected).

Fields of papers citing papers by Joseph I. Clark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph I. Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph I. Clark. The network helps show where Joseph I. Clark may publish in the future.

Co-authorship network of co-authors of Joseph I. Clark

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph I. Clark. A scholar is included among the top collaborators of Joseph I. Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph I. Clark. Joseph I. Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P1026 Rectal stump surveillance in the IBD population 2025 ·Journal of Crohn s and Colitis ·Joseph I. Clark, (unknown), Dominic King	0
2	Implementing a cognitive behavioral intervention for patients with head and neck cancer 2023 ·Supportive Care in Cancer ·(unknown), Patricia Mumby, James Sinacore, Joseph I. Clark, (unknown)	7
3	Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial 2023 ·The Lancet ·Christopher W. Ryan, Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva, Sumanta K. Pal, Igor Puzanov, Joseph I. Clark, Toni K. Choueiri, Neeraj Agarwal, Robert G. Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian Shuch, Ian M. Thompson, Primo N. Lara	21
4	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2 2021 ·Journal of Investigative Medicine ·Joseph I. Clark, Brendan D. Curti, Elizabeth J. Davis, Howard L. Kaufman, Asim Amin, Ajjai Alva, Theodore F. Logan, Ralph J. Hauke, (unknown), Ulka N. Vaishampayan, Douglas B. Johnson, Richard L. White, Peter H. Wiernik, Janice P. Dutcher	15
5	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report 2018 ·Journal for ImmunoTherapy of Cancer ·Joseph I. Clark, (unknown), Shruti Singh, Ewa Borys	0
6	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma 2018 ·Journal for ImmunoTherapy of Cancer ·Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan D. Curti, Sanjiv S. Agarwala, Bret Taback, Lee D. Cranmer, Jose Lutzky, (unknown), Sandra Aung, David H. Lawson	13
7	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry 2017 ·Journal for ImmunoTherapy of Cancer ·Brendan D. Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, (unknown), (unknown), (unknown), Michael A. Morse, Michael K. Wong, Janice P. Dutcher	27
8	Multidisciplinary treatment of olfactory neuroblastoma: Patterns of failure and management of recurrence 2015 ·American Journal of Otolaryngology ·G J Petruzzelli, Jamie B. Howell, Aaron Pederson, Thomas C. Origitano, (unknown), Lorenzo Muñoz, Bahman Emami, Joseph I. Clark	29
9	Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma 2012 ·Investigational New Drugs ·Tara C. Gangadhar, Joseph I. Clark, Theodore Karrison, Thomas F. Gajewski	39
10	CLINICOPATHOLOGICAL REVIEW 2009 ·Neurosurgery ·(unknown), (unknown), Amin Kassam, Bahman Emami, Henry G. Brown, Lotfi Hacein‐Bey, Joseph I. Clark, (unknown), Nicholas M. Boulis, Vikram C. Prabhu	13
11	A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer 2008 ·Clinical Genitourinary Cancer ·Richard T. Lee, (unknown), Maha Hussain, Nancy B. Davis, Joseph I. Clark, Sachdev Thomas, (unknown), Walter M. Stadler	27
12	Evaluation of interferon alpha‐2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026 2007 ·Cancer ·Laura F. Hutchins, James Moon, Joseph I. Clark, John A. Thompson, (unknown), Lawrence E. Flaherty, Vernon K. Sondak	6
13	Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study 2007 ·Journal of Immunotherapy ·Joseph I. Clark, (unknown), Jeffrey A. Sosman, Theodore F. Logan, Kim Margolin, Janice P. Dutcher, Walter J. Urba, Marc S. Ernstoff, David F. McDermott, (unknown), Michael B. Atkins	4
14	Metastatic Juxtaglomerular Cell Tumor in a 52-Year-Old Man 2004 ·The American Journal of Surgical Pathology ·Xiuzhen Duan, Patrick Bruneval, Rasheed Hammadeh, Raoul Fresco, John N. Eble, Joseph I. Clark, Wickii T. Vigneswaran, Robert C. Flanigan, Maria M. Picken	80
15	Case Report and Brief Review: IL-2 Induced Myocarditis 2004 ·Cancer Investigation ·(unknown), Aliya N. Husain, Joseph I. Clark	13
16	Role of Cytokines in Pathology of Melanoma and Use of Biologic Response Modifiers in Melanoma 2003 ·Humana Press eBooks ·Joseph I. Clark	1
17	Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis 2002 ·Human Pathology ·(unknown), Madhu Dahiya, Joseph I. Clark, Steven Creech, Serhan Alkan	78
18	Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer breakdown → 2001 ·The Journal of Immunology ·Bond Almand, Joseph I. Clark, Ekaterina Nikitina, (unknown), Nicholas R. English, Stella C. Knight, David P. Carbone, Dmitry I. Gabrilovich	1052
19	Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma 2001 ·Cancer ·Joseph I. Clark, Craig C. Hofmeister, (unknown), Gregory J. Matz, Sharon L. Collins, Robert W. Bastian, Edward Melian, Bahman Emami, Guy J. Petruzzelli	39
20	Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. 1995 ·PubMed ·Louis M. Weiner, Joseph I. Clark, Michael P. Davey, (unknown), (unknown), David B. Ring, R. Katherine Alpaugh	112

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact